Boehringer Ingelheim International GmbH — commonly "Boehringer Ingelheim" — is a German pharmaceutical group headquartered in Ingelheim am Rhein, Rhineland-Palatinate, Germany. Founded in 1885, it is wholly owned by the family holding C. H. Boehringer Sohn AG & Co. KG and is privately held (no public ticker). Per the company's 2025 annual report, the group employed an average of roughly 54,300 people and reported net sales of about EUR 27.75 billion, with R&D spending of roughly EUR 6.35 billion (about 23% of sales).
Operations. Boehringer Ingelheim is an operating research-based pharmaceutical company, not an NPE. Its two reporting segments are Human Pharma (about 82% of sales) and Animal Health (about 18%). Human Pharma spans cardiometabolic, renal and metabolic health, oncology, respiratory, immunology, retinal health and CNS, with marketed products including JARDIANCE, OFEV, TRADJENTA and SPIRIVA; newer launches include JASCAYD (nerandomilast) and HERNEXEOS (zongertinib). The BioXcellence unit provides biopharmaceutical contract manufacturing, and Animal Health sells vaccines, parasiticides and therapeutics such as NEXGARD. The group operates manufacturing and R&D sites across Europe, the Americas and Asia.
Litigation posture. In the tracked data Boehringer Ingelheim appears once, as plaintiff, with zero defendant cases — consistent with a brand pharmaceutical company enforcing its Orange Book patents against generic ANDA filers under the Hatch-Waxman framework. It is not a patent assertion entity. The single tracked matter was filed in the U.S. District Court for the District of Delaware, a standard venue for ANDA litigation (not the plaintiff-friendly Eastern District of Texas).
Notable case. Boehringer Ingelheim Pharmaceuticals Inc. et al. v. Granules India Limited, No. 1:25-cv-00663 (D. Del., filed May 29, 2025), naming Boehringer Ingelheim International GmbH and affiliates as plaintiffs against Granules India Limited and Granules Pharmaceuticals, Inc. The docket lists patents 9,949,998; 10,258,637; 11,090,323; and 11,833,166 and records a 30-month stay with an October 2027 deadline. A consent judgment closing the case was entered September 2, 2025, before Judge Colm F. Connolly; the underlying product or license terms are not disclosed in the public record.